Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MN-001 (tipelukast) is a novel, leukotriene receptor antagonist which inhibits phosphodiesterase and 5-lipoxygenase and is believed to reduce inflammation and prevent fibrosis. It received a notice of allowance for a new patent for treating advanced NASH...
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2023
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MN-001 (tipelukast) is a novel, orally administered, small molecule compound which reduces triglycerides (TG) in the blood. It has being investigated for the treatment or maintainence of type 2 diabetes and hypertriglyceridemia.
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2023
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MN-001 (tipelukast), is a novel, orally administered, small molecule leukotriene receptor antagonist which inhibits phosphodiesterase (mainly 3 and 4) and 5-lipoxygenase (5-LO) and is believed to reduce inflammation and prevent fibrosis.
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2023
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tipelukast
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MN-001 (tipelukast), an orally administered, small molecule compound with multiple mechanisms of action which has been in clinical development for the treatment of chronic inflammatory and fibrotic diseases, among others, due to its anti-inflammatory and...
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : Tipelukast
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MN-001 (tipelukast) is small molecule compound thought to exert effects through mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including LT receptor antagonism, inhibition of phosphodiesterases, and inhibiti...
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2022
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Juntendo University
Deal Size : Undisclosed
Deal Type : Collaboration
Details : MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor an...
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 22, 2022
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Juntendo University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results from Phase 2a study in NASH/NAFLD patients with hypertriglyceridemia in which MN-001(tipelukast) was shown to reduce serum triglycerides, increase high-density lipoproteins (HDL-C), and reduce low-density lipoproteins during 12-week treatment per...
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2022
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Korean Intellectual Property Office
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Allowed claims cover MN-001 (tipelukast), small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models and MN-002 for treatment of a patient with advance...
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2022
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Korean Intellectual Property Office
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The allowed claims cover a pharmaceutical composition comprising MN-001 (tipelukast) for reducing a triglyceride blood level, reducing a total cholesterol blood level, and reducing a low-density lipoprotein (LDL) blood level.
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 01, 2022
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models.
Brand Name : MN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 26, 2022
Lead Product(s) : Tipelukast
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?